Search
Ascorbyl phosphate
go.drugbank.com/drugs/DB11352ApprovedInvestigationalC that is readily absorbed into the skin with a hydrating effect on the skin [A27212]. … These salts are present in cosmetic products at concentrations ranging from 0.001 % to 3% [A27211].
Adakitug
go.drugbank.com/drugs/DB05484InvestigationalTrials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. … In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice.
Chlorine
go.drugbank.com/drugs/DB11109ApprovedInvestigationalChlorine is a stongly oxidizing agent and the third most electronegative element which belongs to the group of halogens with the atomic number 17 and symbol Cl. … Being a yellow-green gas at room temperature, chlorine is the second most abundant halogen on Earth. It is commonly used in sanitation, disinfection and antiseptic processes.
Keyhole limpet hemocyanin
go.drugbank.com/drugs/DB05299ApprovedInvestigationalWithdrawnKeyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. … Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins.
LP-2307
go.drugbank.com/drugs/DB17470ExperimentalLP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Metformin C-11
go.drugbank.com/drugs/DB15181ExperimentalMetformin c-11 is under investigation in clinical trial NCT03122769 (Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography).
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedIt is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
Domofenogene zalfaparvovec
go.drugbank.com/drugs/DB16810InvestigationalDomofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.